Benjamin Dieplinger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Benjamin Dieplinger has a total of 150 co-authors. Here are the top co-authors by number of shared publications:
Thomas Mueller
Department of Clinical Pathology, Hospital of Bolzano, Bolzano, Italy
13 shared publicationsMargot Egger
Department of Laboratory Medicine , Konventhospital Barmherzige Brueder Linz and Ordensklinikum Linz Barmherzige Schwestern , Linz , Austria
12 shared publicationsMeinhard Haltmayer
Department of Laboratory Medicine, Konventhospital Barmherzige Brueder Linz, Linz, Austria
8 shared publicationsWerner Poelz
Institute for Applied System Sciences and Statistics, University of Linz, Linz, Austria
4 shared publicationsChristian Bundschuh
Department of Laboratory Medicine , Konventhospital Barmherzige Brueder Linz and Ordensklinikum Linz Barmherzige Schwestern , Linz , Austria
3 shared publications- Christian Gabriel
Department of Molecular Biology, Transfusion Service of Upper Austria, Linz, Austria
3 shared publications
Latest Publications
- Open Access
- 24 November 2022
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 19 (23) , 15581
High Anti-CoV2S Antibody Levels at Hospitalization Are Associated with Improved Survival in Patients with COVID-19 Vaccine Breakthrough Infection
Background: Although vaccination against COVID-19 is highly effective, breakthrough infections occur, often leading to severe courses and death. The extent of protection provided by individual antibody levels in breakthrough infections is still unknown and cut-off levels have yet to be determined. Methods: In 80 consecutive fully vaccinated patients hospitalized between August and December 2021 with COVID-19 breakthrough infection (Delta variant), anti-CoV2S antibody levels were analyzed for the endpoint of death. Results: Ten out of the 12 patients who died (83.3%) had antibody levels < 600 U/mL; 5 (41.7%) of these had antibody levels < 200 U/mL. Only 2 patients with a level of >600 U/mL died from vaccine breakthrough infection. Correction for the number of comorbidities and age revealed that anti-CoV2S antibody levels at the time of hospitalization were a significant predictor for reduced risk of death (OR = 0.402 for every 1000 U/mL, p = 0.018). Conclusions: In this retrospective data analysis, we show that almost all patients who died from COVID-19 vaccine breakthrough infection had antibody levels < 600 U/mL, most of them below 200 U/mL. In logistic regression corrected for the number of comorbidities and age, anti-CoV2S antibody levels at the time of hospitalization proved to be a significantly protective predictor against death.
- 24 November 2022
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 19 (23) , 15581
Open AccessHigh Anti-CoV2S Antibody Levels at Hospitalization Are Associated with Improved Survival in Patients with COVID-19 Vaccine Breakthrough Infection
Background: Although vaccination against COVID-19 is highly effective, breakthrough infections occur, often leading to severe courses and death. The extent of protection provided by individual antibody levels in breakthrough infections is still unknown and cut-off levels have yet to be determined. Methods: In 80 consecutive fully vaccinated patients hospitalized between August and December 2021 with COVID-19 breakthrough infection (Delta variant), anti-CoV2S antibody levels were analyzed for the endpoint of death. Results: Ten out of the 12 patients who died (83.3%) had antibody levels < 600 U/mL; 5 (41.7%) of these had antibody levels < 200 U/mL. Only 2 patients with a level of >600 U/mL died from vaccine breakthrough infection. Correction for the number of comorbidities and age revealed that anti-CoV2S antibody levels at the time of hospitalization were a significant predictor for reduced risk of death (OR = 0.402 for every 1000 U/mL, p = 0.018). Conclusions: In this retrospective data analysis, we show that almost all patients who died from COVID-19 vaccine breakthrough infection had antibody levels < 600 U/mL, most of them below 200 U/mL. In logistic regression corrected for the number of comorbidities and age, anti-CoV2S antibody levels at the time of hospitalization proved to be a significantly protective predictor against death.
- Open Access
- 19 July 2022
- Published by Wolters Kluwer Health in Shock
- Vol. 58 (1) , 14-19
SUBCLINICAL KIDNEY INJURY IS CAUSED BY A MODERATE SINGLE INFLAMMATORY EVENT
Background: Current means of diagnosis of acute kidney injury (AKI) based on serum creatinine have poor sensitivity and may miss possible therapeutic windows in subclinical kidney injury, especially in septic AKI. Kidney injury molecule-1 (KIM-1) may be a valuable biomarker to improve diagnostic algorithms for AKI. The understanding of septic AKI is still insufficient, and knowledge about KIM-1 kinetics in inflammation is scarce. The aim of this study was to investigate the possible effect of lipopolysaccharide (LPS) on KIM-1 as a marker of structural kidney injury in healthy volunteers. Methods: A single-blinded, placebo-controlled cross-over study using the human endotoxin model (LPS administration) was performed in 10 healthy men. Kidney injury molecule-1 and serum creatinine were measured repetitively for 48 hours. Results: We observed a significant elevation of serum KIM-1 levels after the administration of LPS (P < 0.001). Furthermore, LPS caused a significant elevation of serum creatinine at an early time point (P = 0.013) as compared with placebo. Conclusion: Even a relatively small inflammatory stimulus is sufficient to cause subclinical structural kidney injury with elevated KIM-1 and serum creatinine in healthy volunteers. This outlines the insufficiency of the current diagnostic approach regarding AKI and the urgency to develop novel diagnostic algorithms including markers of kidney injury. Clinical Trial Registration: www.clinicaltrials.gov. Unique identifier: NCT03392701 (August 1, 2018)
- 19 July 2022
- Published by Wolters Kluwer Health in Shock
- Vol. 58 (1) , 14-19
Open AccessSUBCLINICAL KIDNEY INJURY IS CAUSED BY A MODERATE SINGLE INFLAMMATORY EVENT
Background: Current means of diagnosis of acute kidney injury (AKI) based on serum creatinine have poor sensitivity and may miss possible therapeutic windows in subclinical kidney injury, especially in septic AKI. Kidney injury molecule-1 (KIM-1) may be a valuable biomarker to improve diagnostic algorithms for AKI. The understanding of septic AKI is still insufficient, and knowledge about KIM-1 kinetics in inflammation is scarce. The aim of this study was to investigate the possible effect of lipopolysaccharide (LPS) on KIM-1 as a marker of structural kidney injury in healthy volunteers. Methods: A single-blinded, placebo-controlled cross-over study using the human endotoxin model (LPS administration) was performed in 10 healthy men. Kidney injury molecule-1 and serum creatinine were measured repetitively for 48 hours. Results: We observed a significant elevation of serum KIM-1 levels after the administration of LPS (P < 0.001). Furthermore, LPS caused a significant elevation of serum creatinine at an early time point (P = 0.013) as compared with placebo. Conclusion: Even a relatively small inflammatory stimulus is sufficient to cause subclinical structural kidney injury with elevated KIM-1 and serum creatinine in healthy volunteers. This outlines the insufficiency of the current diagnostic approach regarding AKI and the urgency to develop novel diagnostic algorithms including markers of kidney injury. Clinical Trial Registration: www.clinicaltrials.gov. Unique identifier: NCT03392701 (August 1, 2018)
- 11 January 2021
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 59 (6) , e231-e234
Prevalence of SARS-CoV-2 antibodies in health care personnel of two acute care hospitals in Linz, Austria
Article Prevalence of SARS-CoV-2 antibodies in health care personnel of two acute care hospitals in Linz, Austria was published on January 8, 2021 in the journal Clinical Chemistry and Laboratory Medicine (CCLM) (volume 0, issue 0).
- 11 January 2021
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 59 (6) , e231-e234
Prevalence of SARS-CoV-2 antibodies in health care personnel of two acute care hospitals in Linz, Austria
Article Prevalence of SARS-CoV-2 antibodies in health care personnel of two acute care hospitals in Linz, Austria was published on January 8, 2021 in the journal Clinical Chemistry and Laboratory Medicine (CCLM) (volume 0, issue 0).
- 1 October 2020
- Published by Elsevier in Clinica Chimica Acta
- Vol. 509, 79-82
Evaluation of the EDI enzyme linked immunosorbent assays for the detection of SARS-CoV-2 IgM and IgG antibodies in human plasma
- 1 October 2020
- Published by Elsevier in Clinica Chimica Acta
- Vol. 509, 79-82
Evaluation of the EDI enzyme linked immunosorbent assays for the detection of SARS-CoV-2 IgM and IgG antibodies in human plasma
- 1 April 2020
- Published by Elsevier in American Journal of Infection Control
- Vol. 48 (4) , 386-390
Implementation of a comprehensive unit-based safety program to reduce surgical site infections in cesarean delivery
- 1 April 2020
- Published by Elsevier in American Journal of Infection Control
- Vol. 48 (4) , 386-390
Implementation of a comprehensive unit-based safety program to reduce surgical site infections in cesarean delivery
- Open Access
- 22 January 2018
- Published by AME Publishing Company in Journal of Laboratory and Precision Medicine
- Vol. 3 (1) , 5
Afamin an emerging marker for type 2 diabetes mellitus
- 22 January 2018
- Published by AME Publishing Company in Journal of Laboratory and Precision Medicine
- Vol. 3 (1) , 5
Open AccessAfamin an emerging marker for type 2 diabetes mellitus
- 1 June 2017
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 63 (6) , 1101-1109
Prognostic Value of Inflammatory and Cardiovascular Biomarkers for Prediction of 90-Day All-Cause Mortality after Acute Ischemic Stroke—Results from the Linz Stroke Unit Study
BACKGROUND: Early outcome prediction after acute ischemic stroke is of great interest. The aim of our study was to evaluate the prognostic value of blood biomarkers in patients with acute ischemic stroke. METHODS: We measured interleukin-6 (IL-6), d-dimer, amino-terminal pro–B-type natriuretic peptide (NT-proBNP), high-sensitivity cardiac troponin T, and soluble ST2 plasma concentrations within 24 h after admission to our stroke unit in 721 consecutive acute ischemic stroke patients. End point was 90-day all-cause mortality. RESULTS: During follow-up 81 patients died (11%). In univariate Cox proportional hazards regression analyses with the biochemical markers dichotomized according to median values, all baseline blood biomarkers were strong prognostic markers. However, in the multivariate analysis after adjustment for several clinical variables and the NIH Stroke Scale (NIHSS), only NIHSS >3 [risk ratio (RR) 7.87, 95% CI, 3.61–17.16; P < 0.001], IL-6 > 7 pg/mL (RR 4.09, 95% CI, 2.02–8.29; P < 0.001), and NT-proBNP >447 ng/L (RR 4.88, 95% CI, 2.41–9.88; P < 0.001) remained independent predictors. Using a simple multimarker approach combining these 3 complementary markers, we demonstrated that patients with increased NIHSS, IL-6, and NT-proBNP had the poorest outcome with a mortality rate of 38%, whereas no patient with negative readings for all 3 markers died during follow-up. CONCLUSIONS: In this large cohort of patients with acute ischemic stroke, IL-6 and NT-proBNP at admission were strong and independent prognostic markers for 90-day all-cause mortality, and provided complementary prognostic information to the routinely used stroke severity score NIHSS.
- 1 June 2017
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 63 (6) , 1101-1109
Prognostic Value of Inflammatory and Cardiovascular Biomarkers for Prediction of 90-Day All-Cause Mortality after Acute Ischemic Stroke—Results from the Linz Stroke Unit Study
BACKGROUND: Early outcome prediction after acute ischemic stroke is of great interest. The aim of our study was to evaluate the prognostic value of blood biomarkers in patients with acute ischemic stroke. METHODS: We measured interleukin-6 (IL-6), d-dimer, amino-terminal pro–B-type natriuretic peptide (NT-proBNP), high-sensitivity cardiac troponin T, and soluble ST2 plasma concentrations within 24 h after admission to our stroke unit in 721 consecutive acute ischemic stroke patients. End point was 90-day all-cause mortality. RESULTS: During follow-up 81 patients died (11%). In univariate Cox proportional hazards regression analyses with the biochemical markers dichotomized according to median values, all baseline blood biomarkers were strong prognostic markers. However, in the multivariate analysis after adjustment for several clinical variables and the NIH Stroke Scale (NIHSS), only NIHSS >3 [risk ratio (RR) 7.87, 95% CI, 3.61–17.16; P < 0.001], IL-6 > 7 pg/mL (RR 4.09, 95% CI, 2.02–8.29; P < 0.001), and NT-proBNP >447 ng/L (RR 4.88, 95% CI, 2.41–9.88; P < 0.001) remained independent predictors. Using a simple multimarker approach combining these 3 complementary markers, we demonstrated that patients with increased NIHSS, IL-6, and NT-proBNP had the poorest outcome with a mortality rate of 38%, whereas no patient with negative readings for all 3 markers died during follow-up. CONCLUSIONS: In this large cohort of patients with acute ischemic stroke, IL-6 and NT-proBNP at admission were strong and independent prognostic markers for 90-day all-cause mortality, and provided complementary prognostic information to the routinely used stroke severity score NIHSS.
- Open Access
- 24 February 2017
- Published by Springer Nature in Wiener Medizinische Wochenschrift
- Vol. 168 (5-6) , 133-143
Edoxaban zur Schlaganfallprophylaxe bei Patienten mit nicht-valvulärem Vorhofflimmern und zur Behandlung venöser Thromboembolien: ein interdisziplinäres Positionspapier
Mit Edoxaban ist der nun neueste Vertreter der Nicht-Vitamin K Antagonisten Oralen Antikoagulanzien (NOAK) verfügbar. Die Zulassung erfolgte auf Basis der zwei bisher größten Phase III Studien in der Indikation Schlaganfallprophylaxe bei nicht-valvulärem Vorhofflimmern (VHF, ENGAGE-AF) als auch bei der Behandlung von venösen Thromboembolien (VTE, HOKUSAI-VTE). In beiden Zulassungsstudien fand sich bei vergleichbarer Effektivität gegenüber Warfarin eine signifikante Reduktion von Blutungsereignissen gemäß der vordefinierten primären Sicherheitsendpunkte. Zudem ergeben sich aufgrund der einmal täglichen, nahrungsunabhängigen Anwendung, einer eigens untersuchten Strategie zur Dosisreduktion, und dem ansprechenden pharmakokinetischen Profil weitere Vorteile in der klinischen Praxis. Eine interdisziplinäre Expertengruppe nimmt dies zum Anlass, die rezenten Studiendaten und Empfehlungen der nationalen und internationalen Leitlinien in ihrer Kurzform zu skizzieren sowie ein Positionspapier zum Management von Risikopatienten mit nicht-valvulärem VHF sowie der Behandlung von VTE zu formulieren. Edoxaban is the most recent available representative of the Non-Vitamin K antagonist oral anticoagulants (NOAC). The approval was based on the largest phase III trials of NOACs for stroke prevention in patients with non-valvular atrial fibrillation (AF, ENGAGE-AF), and for the treatment of venous thromboembolism (VTE, HOKUSAI-VTE). In both trials, edoxaban was associated with similar efficacy and a significant reduction in bleeding events with respect to the pre-defined primary safety endpoints, as compared to warfarin. Additionally, the once daily dosing of edoxaban, the clinically investigated strategy for dose-reduction based on clearly defined criteria and the favorable pharmacokinetic profile might further support the clinical applicability of the substance. In the light of recent data, this expert consensus document aims to summarize the latest clinical trial results while providing a concise overview of current guideline recommendations on the management of patients with non-valvular AF and VTE.
- 24 February 2017
- Published by Springer Nature in Wiener Medizinische Wochenschrift
- Vol. 168 (5-6) , 133-143
Open AccessEdoxaban zur Schlaganfallprophylaxe bei Patienten mit nicht-valvulärem Vorhofflimmern und zur Behandlung venöser Thromboembolien: ein interdisziplinäres Positionspapier
Mit Edoxaban ist der nun neueste Vertreter der Nicht-Vitamin K Antagonisten Oralen Antikoagulanzien (NOAK) verfügbar. Die Zulassung erfolgte auf Basis der zwei bisher größten Phase III Studien in der Indikation Schlaganfallprophylaxe bei nicht-valvulärem Vorhofflimmern (VHF, ENGAGE-AF) als auch bei der Behandlung von venösen Thromboembolien (VTE, HOKUSAI-VTE). In beiden Zulassungsstudien fand sich bei vergleichbarer Effektivität gegenüber Warfarin eine signifikante Reduktion von Blutungsereignissen gemäß der vordefinierten primären Sicherheitsendpunkte. Zudem ergeben sich aufgrund der einmal täglichen, nahrungsunabhängigen Anwendung, einer eigens untersuchten Strategie zur Dosisreduktion, und dem ansprechenden pharmakokinetischen Profil weitere Vorteile in der klinischen Praxis. Eine interdisziplinäre Expertengruppe nimmt dies zum Anlass, die rezenten Studiendaten und Empfehlungen der nationalen und internationalen Leitlinien in ihrer Kurzform zu skizzieren sowie ein Positionspapier zum Management von Risikopatienten mit nicht-valvulärem VHF sowie der Behandlung von VTE zu formulieren. Edoxaban is the most recent available representative of the Non-Vitamin K antagonist oral anticoagulants (NOAC). The approval was based on the largest phase III trials of NOACs for stroke prevention in patients with non-valvular atrial fibrillation (AF, ENGAGE-AF), and for the treatment of venous thromboembolism (VTE, HOKUSAI-VTE). In both trials, edoxaban was associated with similar efficacy and a significant reduction in bleeding events with respect to the pre-defined primary safety endpoints, as compared to warfarin. Additionally, the once daily dosing of edoxaban, the clinically investigated strategy for dose-reduction based on clearly defined criteria and the favorable pharmacokinetic profile might further support the clinical applicability of the substance. In the light of recent data, this expert consensus document aims to summarize the latest clinical trial results while providing a concise overview of current guideline recommendations on the management of patients with non-valvular AF and VTE.